News and Announcements
Bioactive Laboratories Pty Ltd – CEO Interview
- Published June 25, 2014 3:34PM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Bioactive Laboratories specialises in plant based solutions for human health.
They have developed the first anti-inflammatory and pain relieving agent that is gentle to the stomach. Studies show it rivals the drug efficacy and strength of NSAIDs such as Voltaren, without digestive side effects.
Global market sectors worth an estimated $560Billion annually make anti-inflammatories & pain agents the most widely used of all drugs and complementary medicines.
A faster route to market exists, than traditional biotech via the booming Complementary Medicine market to supply bulk powders & extracts.
Profitability within four years is predicted via a conservative financial model. This hybrid complementary medicine/drug development business model, suggests self funding for the development pipeline that includes drug candidates & revolutionary plant based solutions for type-2 diabetes.
Customers such as pharmaceutical & complementary medicine companies have been approached and are anxious to gain access.
To hear the latest on Bioactive Laboratories straight from the source, please listen to Rick Ferdinands, Founder & MD.
Executive Interviews
What is a Wholesale Investor in Australia? Complete 2026 Guide
What is a Wholesale Investor in Australia? A wholesale investor is an individual or entity that meets specific financial thresholds set out in the Corporations Act 2001 (Cth), qualifying them to access investment opportunities that are not available to general retail investors. These include private equity rounds, venture capital deals, pre-IPO placements, alternative funds, and […]
Why the 20-Year Hold Is the Secret to Australian Life Sciences Returns
Australia represents 0.3% of the world’s population. Yet it generates more than 3% of global research output. Cochlear implants. Wi-Fi. The HPV vaccine. These are not statistical anomalies. They are proof points of a structural advantage that Australia has failed to capitalise on. The country has a world-class research base. But it watches companies scale […]
The ‘Unused Billion’: How Points4Purpose is Disrupting the Flatlining Loyalty Market
The loyalty industry is plagued by “sameness,” leaving billions in value dormant. Ivan Schwartz’s Points4Purpose is disrupting this flatlining market by turning rewards into a liquid currency for rent, bills, and over 1.8 million charities.
Backed By Leading Investment Groups and Family Offices
